NasdaqCM - Nasdaq Real Time Price USD

Pluri Inc. (PLUR)

5.75
+0.44
+(8.29%)
At close: May 9 at 4:00:01 PM EDT
5.94
+0.19
+(3.30%)
After hours: May 9 at 5:42:06 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
678
326
287
234
0
Cost of Revenue
204
4
9
0
0
Gross Profit
474
322
278
234
0
Operating Expense
22,197
22,480
27,524
41,827
50,623
Operating Income
-21,723
-22,158
-27,246
-41,593
-50,623
Net Non Operating Interest Income Expense
322
540
225
-331
391
Other Income Expense
1,003
274
-1,866
550
367
Pretax Income
-20,398
-21,344
-28,887
-41,374
-49,865
Net Income Common Stockholders
-19,860
-20,888
-28,321
-41,242
-49,865
Diluted NI Available to Com Stockholders
-19,860
-20,888
-28,321
-41,242
-49,865
Basic EPS
-3.68
-3.99
-6.24
-10.24
-14.16
Diluted EPS
-3.68
-3.99
-6.24
-10.24
-14.16
Basic Average Shares
5,403.93
5,240.25
4,581.50
4,024.01
3,514.20
Diluted Average Shares
5,403.93
5,240.25
4,581.50
4,024.01
3,514.20
Total Operating Income as Reported
-21,723
-22,158
-27,246
-41,593
-50,623
Total Expenses
22,401
22,484
27,533
41,827
50,623
Net Income from Continuing & Discontinued Operation
-19,860
-20,888
-28,321
-41,242
-49,865
Normalized Income
-20,863
-21,162
-26,455
-41,792
-50,232
Interest Income
1,094
1,314
1,084
581
492
Interest Expense
864
866
843
887
78
Net Interest Income
322
540
225
-331
391
EBIT
-19,534
-20,478
-28,044
-40,487
-49,787
EBITDA
-19,279
-20,225
-27,682
-39,434
-48,417
Reconciled Cost of Revenue
204
4
9
0
0
Reconciled Depreciation
255
253
362
1,053
1,370
Net Income from Continuing Operation Net Minority Interest
-19,860
-20,888
-28,321
-41,242
-49,865
Total Unusual Items Excluding Goodwill
1,003
274
-1,866
550
367
Total Unusual Items
1,003
274
-1,866
550
367
Normalized EBITDA
-20,282
-20,499
-25,816
-39,984
-48,784
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
6/30/2021 - 6/30/2003

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CGEN Compugen Ltd.
1.2600
-2.33%
 
BLRX BioLineRx Ltd.
3.1700
-0.94%
 
CANF Can-Fite BioPharma Ltd.
1.1100
-0.45%
 
ENLV Enlivex Therapeutics Ltd.
1.0200
-2.86%
 
PLX Protalix BioTherapeutics, Inc.
1.7200
-40.48%
 
XTLB XTL Biopharmaceuticals Ltd.
1.2600
+1.61%
 
BCLI Brainstorm Cell Therapeutics Inc.
1.1800
-3.28%
 
SABS SAB Biotherapeutics, Inc.
1.7900
+3.47%
 
NTHI NeOnc Technologies Holdings, Inc.
7.34
+11.21%
 
EVGN Evogene Ltd.
1.1325
+0.22%